Silence Therapeutics (SLN) Gains from Investment Securities: 2022-2025
Historic Gains from Investment Securities for Silence Therapeutics (SLN) over the last 2 years, with Sep 2025 value amounting to -$2.9 million.
- Silence Therapeutics' Gains from Investment Securities fell 929.18% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of $17.5 million for FY2024, which is 442.60% up from last year.
- As of Q3 2025, Silence Therapeutics' Gains from Investment Securities stood at -$2.9 million, which was down 588.57% from -$420,000 recorded in Q2 2025.
- Silence Therapeutics' Gains from Investment Securities' 5-year high stood at $19.7 million during Q4 2023, with a 5-year trough of -$2.9 million in Q3 2025.
- In the last 3 years, Silence Therapeutics' Gains from Investment Securities had a median value of -$138,500 in 2024 and averaged $2.9 million.
- As far as peak fluctuations go, Silence Therapeutics' Gains from Investment Securities surged by 44.97% in 2023, and later plummeted by 929.18% in 2025.
- Over the past 4 years, Silence Therapeutics' Gains from Investment Securities (Quarterly) stood at $13.6 million in 2022, then surged by 44.97% to $19.7 million in 2023, then crashed by 62.61% to $7.4 million in 2024, then tumbled by 929.18% to -$2.9 million in 2025.
- Its last three reported values are -$2.9 million in Q3 2025, -$420,000 for Q2 2025, and -$89,000 during Q1 2025.